Erenxa Therapeutics Inc. (ERNA) filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 16, 2026. The filing was submitted by the Delaware corporation, which is headquartered at 1035 Cambridge Street, Suite 18A in Cambridge, Massachusetts. The company’s principal executive offices are located at this address, and its telephone number is (617) 798-6700.
The report, filed under the ticker symbol ERNA on The Nasdaq Stock Market LLC, details the company’s disclosure of corporate materials. Specifically, the registrant made available a corporate fact sheet and an investor presentation for September 2026. These documents are attached to the filing as Exhibits 99.1 and 99.2, respectively.
The company stated that copies of the fact sheet and presentation will be available on its investor relations website, https://investor.ernexatx.com, beginning September 17, 2026. The filing notes that the information furnished in these exhibits is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934.
